Key result
Dalteparin prophylaxis for deep-vein thrombosis after hip or knee arthroplasty lowered the age-adjusted risk of DVT and bleeding compared to enoxaparin, saving $129 per patient.
Why the study?
Does dalteparin reduce DVT events, bleeding, and costs compared to enoxaparin in patients undergoing inpatient rehabilitation after total hip or knee arthroplasty?
Cohort (n=461)
No
Does dalteparin reduce DVT events, bleeding, and costs compared to enoxaparin in patients undergoing inpatient rehabilitation after total hip or knee arthroplasty?
Switching from enoxaparin to dalteparin for DVT prophylaxis during rehabilitation after joint arthroplasty may reduce DVT incidence, bleeding events, and costs.
Answers are grounded in this paper and cite their sources.
May support dalteparin preference post-arthroplasty; leaves open randomized confirmation of benefits.
Krotenberg R, Adler U, Pomeranz B, Miller JD, Russel MW: Dalteparin vs. enoxaparin as prophylaxis for deep-vein thrombosis after total hip or knee arthroplasty: a retrospective analysis. Am J Phys Med Rehabil 2001;80:889–895. Objective To assess the clinical and economic consequences of a formulary switch from enoxaparin to dalteparin as first-line prophylaxis for deep-vein thrombosis in patients undergoing inpatient rehabilitation after total hip arthroplasty or total knee arthroplasty. Design Retrospective cohort study. Results There were 461 patients eligible for the study. The age-adjusted risk of a deep-vein thrombosis event confirmed by duplex ultrasonography among patients treated with dalteparin was substantially lower than among patients treated with enoxaparin, whereas the age-adjusted risk of a bleeding event in the dalteparin group was also lower than that in the enoxaparin group. Adjusted per capita costs of deep-vein thrombosis prophylaxis during the rehabilitation stay were $129 lower among subjects treated with dalteparin. Conclusion The switch to dalteparin as a first-line therapy for deep-vein thrombosis prophylaxis in the rehabilitation period after total hip arthroplasty or total knee arthroplasty has led to substantial cost savings for Kessler Institute without compromising patient care.
No takes yet. Share an insight, caveat, or question.
Krotenberg et al. (2001) conducted a cohort in Deep-vein thrombosis prophylaxis after total hip or knee arthroplasty (n=461). Dalteparin vs. Enoxaparin was evaluated on Deep-vein thrombosis event confirmed by duplex ultrasonography. Dalteparin prophylaxis for deep-vein thrombosis after hip or knee arthroplasty lowered the age-adjusted risk of DVT and bleeding compared to enoxaparin, saving $129 per patient.
Synapse has enriched 10 related papers. Consider them for comparative context: